GTHX G1 Therapeutics Inc

Price (delayed)

$1.7

Market cap

$88.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$91.18M

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the ...

Highlights
The company's EPS has surged by 61% YoY and by 14% QoQ
The company's net income has surged by 54% YoY and by 9% QoQ
GTHX's revenue has soared by 66% YoY but it is down by 13% QoQ
The gross profit has surged by 62% year-on-year but it has declined by 16% since the previous quarter
GTHX's equity is down by 25% since the previous quarter and by 6% year-on-year
The company's quick ratio fell by 14% YoY and by 11% QoQ

Key stats

What are the main financial stats of GTHX
Market
Shares outstanding
51.84M
Market cap
$88.13M
Enterprise value
$91.18M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.04
Price to sales (P/S)
1.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.17
Earnings
Revenue
$77.89M
EBIT
-$57.13M
EBITDA
-$56.61M
Free cash flow
-$56.18M
Per share
EPS
-$1.42
Free cash flow per share
-$1.08
Book value per share
$0.83
Revenue per share
$1.5
TBVPS
$2.57
Balance sheet
Total assets
$133.1M
Total liabilities
$90.08M
Debt
$55.92M
Equity
$43.02M
Working capital
$92.45M
Liquidity
Debt to equity
1.3
Current ratio
3.75
Quick ratio
3.09
Net debt/EBITDA
-0.05
Margins
EBITDA margin
-72.7%
Gross margin
91.1%
Net margin
-90.8%
Operating margin
-78.9%
Efficiency
Return on assets
-44.8%
Return on equity
-132%
Return on invested capital
-45.8%
Return on capital employed
-57.5%
Return on sales
-73.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GTHX stock price

How has the G1 Therapeutics stock price performed over time
Intraday
0.59%
1 week
2.41%
1 month
11.84%
1 year
-69.86%
YTD
-68.69%
QTD
18.06%

Financial performance

How have G1 Therapeutics's revenue and profit performed over time
Revenue
$77.89M
Gross profit
$70.96M
Operating income
-$61.49M
Net income
-$70.74M
Gross margin
91.1%
Net margin
-90.8%
GTHX's operating margin has surged by 74% year-on-year but it is down by 5% since the previous quarter
GTHX's net margin has soared by 72% YoY but it is down by 4% QoQ
GTHX's revenue has soared by 66% YoY but it is down by 13% QoQ
The gross profit has surged by 62% year-on-year but it has declined by 16% since the previous quarter

Growth

What is G1 Therapeutics's growth rate over time

Valuation

What is G1 Therapeutics stock price valuation
P/E
N/A
P/B
2.04
P/S
1.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.17
The company's EPS has surged by 61% YoY and by 14% QoQ
The P/B is 42% below the 5-year quarterly average of 3.5 and 22% below the last 4 quarters average of 2.6
GTHX's equity is down by 25% since the previous quarter and by 6% year-on-year
GTHX's revenue has soared by 66% YoY but it is down by 13% QoQ
The price to sales (P/S) is 53% lower than the last 4 quarters average of 2.4

Efficiency

How efficient is G1 Therapeutics business performance
The company's return on sales has surged by 76% YoY but it fell by 3.5% QoQ
The ROIC has soared by 70% year-on-year and by 7% since the previous quarter
The ROA has grown by 40% YoY and by 4.3% from the previous quarter
GTHX's ROE is up by 24% YoY and by 8% from the previous quarter

Dividends

What is GTHX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GTHX.

Financial health

How did G1 Therapeutics financials performed over time
The company's total assets is 48% higher than its total liabilities
GTHX's total liabilities is down by 25% year-on-year
The company's total assets fell by 20% YoY and by 10% QoQ
GTHX's debt is 30% higher than its equity
G1 Therapeutics's debt to equity has increased by 34% QoQ but it has decreased by 27% YoY
GTHX's debt is down by 32% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.